These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 8956459)

  • 1. Harnessing self-reactivity in cancer immunotherapy.
    Schoenberger SP; Sercarz EE
    Semin Immunol; 1996 Oct; 8(5):303-9. PubMed ID: 8956459
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cell intrinsic mechanisms of T-cell inhibition and application to cancer therapy.
    Peggs KS; Quezada SA; Allison JP
    Immunol Rev; 2008 Aug; 224():141-65. PubMed ID: 18759925
    [TBL] [Abstract][Full Text] [Related]  

  • 3. How the immune system achieves self-nonself discrimination during adaptive immunity.
    Jiang H; Chess L
    Adv Immunol; 2009; 102():95-133. PubMed ID: 19477320
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of optimized cryptic peptides for immunotherapy.
    Menez-Jamet J; Kosmatopoulos K
    IDrugs; 2009 Feb; 12(2):98-102. PubMed ID: 19204883
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Induction of CD4(+) and CD8(+) T-cell responses to the human stromal antigen, fibroblast activation protein: implication for cancer immunotherapy.
    Fassnacht M; Lee J; Milazzo C; Boczkowski D; Su Z; Nair S; Gilboa E
    Clin Cancer Res; 2005 Aug; 11(15):5566-71. PubMed ID: 16061874
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of p53 on anti-tumor immunity (review).
    Bueter M; Gasser M; Lebedeva T; Benichou G; Waaga-Gasser AM
    Int J Oncol; 2006 Feb; 28(2):519-25. PubMed ID: 16391808
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The self-directed T cell repertoire: its creation and activation.
    Moudgil KD; Sercarz EE
    Rev Immunogenet; 2000; 2(1):26-37. PubMed ID: 11324691
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor-specific immunotherapy based on dominant models of natural tolerance.
    Montero E; Amador JF; Pérez R; Lage A
    Med Hypotheses; 2000 Apr; 54(4):531-6. PubMed ID: 10859636
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Boosting the immune response: an alternative combination therapy for cancer patients.
    Thyphronitis G; Koutsilieris M
    Anticancer Res; 2004; 24(4):2443-53. PubMed ID: 15330197
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytokine, chemokine, and co-stimulatory fusion proteins for the immunotherapy of solid tumors.
    Khawli LA; Hu P; Epstein AL
    Handb Exp Pharmacol; 2008; (181):291-328. PubMed ID: 18071951
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rational design of peptide vaccines for autoimmune disease: harnessing molecular recognition to fix a broken network.
    Weathington NM; Blalock JE
    Expert Rev Vaccines; 2003 Feb; 2(1):61-73. PubMed ID: 12901598
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade.
    Iwai Y; Ishida M; Tanaka Y; Okazaki T; Honjo T; Minato N
    Proc Natl Acad Sci U S A; 2002 Sep; 99(19):12293-7. PubMed ID: 12218188
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune responses to human tumors: development of tumor vaccines.
    Platsoucas CD; Fincke JE; Pappas J; Jung WJ; Heckel M; Schwarting R; Magira E; Monos D; Freedman RS
    Anticancer Res; 2003; 23(3A):1969-96. PubMed ID: 12894571
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Allogeneic GM-CSF-secreting tumor cell immunotherapies generate potent anti-tumor responses comparable to autologous tumor cell immunotherapies.
    Li B; Simmons A; Du T; Lin C; Moskalenko M; Gonzalez-Edick M; VanRoey M; Jooss K
    Clin Immunol; 2009 Nov; 133(2):184-97. PubMed ID: 19664962
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor immunotherapy: preclinical and clinical activity of anti-CTLA4 antibodies.
    Korman A; Yellin M; Keler T
    Curr Opin Investig Drugs; 2005 Jun; 6(6):582-91. PubMed ID: 15988909
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The development of new cancer therapies based on the molecular identification of cancer regression antigens.
    Rosenberg SA
    Cancer J Sci Am; 1995; 1(2):90-100. PubMed ID: 9166458
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adoptive immunotherapy of cancer: accomplishments and prospects.
    Rosenberg SA
    Cancer Treat Rep; 1984 Jan; 68(1):233-55. PubMed ID: 6362866
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regulatory T cells: magic bullets for immunotherapy?
    Frey O; Bräuer R
    Arch Immunol Ther Exp (Warsz); 2006; 54(1):33-43. PubMed ID: 16642255
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A fresh look at tumor immunosurveillance and immunotherapy.
    Smyth MJ; Godfrey DI; Trapani JA
    Nat Immunol; 2001 Apr; 2(4):293-9. PubMed ID: 11276199
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tolerance and cancer: mechanisms of tumor evasion and strategies for breaking tolerance.
    Mapara MY; Sykes M
    J Clin Oncol; 2004 Mar; 22(6):1136-51. PubMed ID: 15020616
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.